Vera Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Class A Common Stock · Class B CommonStock · AdditionalPaid-in · Accumulated Other · Accumulated · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Comprehensive Loss | Deficit | Equity | |
| Balances as of December 31, 2021 | 20,968,376 | $21 | 309,238 | $— | $193,627 | $— | $(124,056) | $69,592 |
| Issuance of Class A common stock from underwritten follow-on offering, net of offering costs | 5,742,026 | 6 | — | — | 80,028 | — | — | 80,034 |
| Issuance of Class A common stock upon exercise of options | 405,140 | 1 | — | — | 1,791 | — | — | 1,792 |
| Issuance of Class A common stock pursuant to employee stock purchase plan | 15,328 | — | — | — | 291 | — | — | 291 |
| Issuance of Class A common stock upon vesting of restricted stock units | 77,719 | — | — | — | — | — | — | — |
| Conversion of Class B common stock into Class A common stock | 309,238 | — | (309,238) | — | — | — | — | — |
| Issuance of Class A common stock for payment of licensing fees, net of offering costs | 283,034 | — | — | — | 5,592 | — | — | 5,592 |
| Stock-based compensation | — | — | — | — | 8,887 | — | — | 8,887 |
| Unrealized loss on marketable securities | — | — | — | — | — | (224) | — | (224) |
| Net loss | — | — | — | — | — | — | (89,056) | (89,056) |
| Balances as of December 31, 2022 | 27,800,861 | $28 | — | $— | $290,216 | $(224) | $(213,112) | $76,908 |
| Issuance of common stock from underwritten follow-on offering, net of offering costs | 16,428,572 | 16 | — | — | 107,727 | — | — | 107,743 |
| Issuance of Class A common stock upon exercise of options | 111,927 | — | — | — | 781 | — | — | 781 |
| Issuance of Class A common stock upon vesting of restricted stock units | 66,321 | — | — | — | — | — | — | - |
| Issuance of Class A common stock pursuant to employee stock purchase plan | 44,480 | — | — | — | 275 | — | — | 275 |
| Stock-based compensation | - | — | — | — | 11,493 | — | — | 11,493 |
| Unrealized gain on marketable securities | — | — | — | — | — | 475 | — | 475 |
| Net loss | — | — | — | — | — | — | (95,990) | (95,990) |
| Balances as of December 31, 2023 | 44,452,161 | $44 | — | $— | $410,492 | $251 | $(309,102) | $101,685 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.